AT&T Inc. vs Cardinal Health, Inc.: Strategic Comparison

This in-depth comparison examines AT&T Inc. and Cardinal Health, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AT&T Inc. on its own, evaluating Cardinal Health, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AT&T Inc. and Cardinal Health, Inc. is widest.

On the headline numbers, AT&T Inc. reports annual revenue of $125.6B against $254.2B for Cardinal Health, Inc., while their respective market capitalizations stand at $174.4B and $56.0B. Both AT&T Inc. and Cardinal Health, Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

AT&T Inc.: AT&T is one of the oldest names in telecommunications and now operates as a capital-heavy network business. It sold wireless service to 74.2 million postpaid phone subscribers at the end of 2025, sells fiber and fixed wireless broadband to households and businesses across the United States, runs business connectivity, and operates wireless networks in Mexico. After a decade-long detour into media through DirecTV and Time Warner, it separated WarnerMedia in 2022 and sold its remaining DIRECTV stake in July 2025, returning to building and running networks.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

AT&T Inc. and Cardinal Health, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AT&T Inc. and Cardinal Health, Inc..

AT&T Inc. business model: AT&T runs a capital-intensive network business. It buys licensed wireless spectrum, builds and upgrades cell sites, and trenches fiber, then charges consumers and businesses a monthly fee to use that network. Capital investment was $22.0 billion in 2025 against $125.6 billion of revenue. Most of the revenue is recurring subscription revenue, so the economics turn on churn: postpaid phone churn was 0.98% in the fourth quarter of 2025. Device sales add about $22.1 billion a year at much lower margin than service.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AT&T Inc. stack up against those of Cardinal Health, Inc..

AT&T Inc. competitive advantage: AT&T's advantage is the cost of replicating what it already owns. Its fiber network passed 32.0 million consumer and business locations at the end of 2025, and its mid-band 5G service covers more than 310 million people. Keeping that going took $22.0 billion of capital investment in 2025 alone, which is why the national market has three carriers rather than thirty. AT&T also builds and operates FirstNet for the FirstNet Authority under a 25-year contract awarded in 2017, a public safety network with more than 7 million connections and no direct equivalent. Because connectivity is sold on monthly subscriptions, revenue moves slowly in both directions.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Future prospects matter as much as current results. The growth strategies below explain how AT&T Inc. and Cardinal Health, Inc. each plan to expand from here.

AT&T Inc. growth strategy: With the US smartphone market saturated, AT&T's growth depends on home internet and on keeping the wireless customers it has. It is building fiber, which passed 32.0 million consumer and business locations at the end of 2025 and carried 10.4 million subscribers, and it sells AT&T Internet Air fixed wireless where fiber is not available. In wireless the emphasis is retention: AT&T offers existing customers the same trade-in promotions as switchers and spreads the credits over 36-month device installment plans, which held postpaid phone churn at 0.98% in the fourth quarter of 2025. The Lumen mass markets fiber purchase, completed in February 2026, added more than 1 million subscribers and more than 4 million fiber locations in metros including Denver, Seattle and Salt Lake City.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

A closer look at the financial trajectory of AT&T Inc. and Cardinal Health, Inc. rounds out the comparison.

AT&T Inc.: AT&T's financial story is large revenue, large debt and a slow correction. The company funded the $48.5 billion DirecTV purchase in 2015 and the $85.4 billion Time Warner purchase in 2018 largely with borrowing, and net debt passed $180 billion after Time Warner closed. It then reversed course: WarnerMedia was separated in 2022, the dividend was cut, and the remaining 70% DIRECTV stake went to TPG in July 2025 for a $5.6 billion gain. FY2025 revenue was $125.6 billion, with $23.4 billion of total net income, $46.4 billion of adjusted EBITDA and $16.6 billion of free cash flow against $117.4 billion of net debt. Roughly $22 billion a year of capital investment goes mostly into fiber and 5G.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.